JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Quote. Real-time Estimate  - 05/16 06:29:05 pm
178.2350 USD   +0.78%
05/13Idaho announces $119 million opioid crisis settlement
AQ
05/13What We're Reading This Week
AQ
05/12Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

US Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers

01/25/2022 | 02:14pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.70% 178.08 Delayed Quote.4.10%
MODERNA, INC. -1.20% 136.26 Delayed Quote.-46.35%
PFIZER, INC. 1.50% 50.67 Delayed Quote.-14.19%
All news about JOHNSON & JOHNSON
05/13Idaho announces $119 million opioid crisis settlement
AQ
05/13What We're Reading This Week
AQ
05/12Johnson & Johnson to Participate in Goldman Sachs 43rd Annual Global Healthcare Confere..
PR
05/12Africa's Covid-19 Vaccine Production Line in Jeopardy
AQ
05/11TRANSCRIPT : Johnson & Johnson Presents at Bank of America 2022 Healthcare Conference, May..
CI
05/11Johnson & Johnson Names Thibaut Mongon CEO Designate of Planned New Consumer Health Com..
MT
05/11Johnson & Johnson Appoints CEO For Future Spin-off Unit
MT
05/11Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Heal..
PR
05/11Johnson & Johnson Announces Management Appointments for Planned New Consumer Health Com..
CI
05/10Emergent Discarded 400 Million Vaccine Doses Over Quality Issues, Congressional Report ..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 249 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 20,0x
Yield 2022 2,50%
Capitalization 469 B 469 B -
EV / Sales 2022 4,78x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 178,08 $
Average target price 187,12 $
Spread / Average Target 5,08%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421
NOVO NORDISK A/S1.92%238 221